Sanctuary Advisors LLC Purchases 32,183 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Sanctuary Advisors LLC boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 82.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,444 shares of the biotechnology company’s stock after buying an additional 32,183 shares during the period. Sanctuary Advisors LLC’s holdings in Exelixis were worth $2,353,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FMR LLC increased its position in Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after buying an additional 140,568 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares in the last quarter. Two Sigma Advisers LP increased its position in Exelixis by 6.1% during the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock valued at $44,182,000 after buying an additional 98,000 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after buying an additional 704,786 shares in the last quarter. Finally, Systematic Financial Management LP increased its position in Exelixis by 7.1% during the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock valued at $30,320,000 after buying an additional 77,599 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of Exelixis stock opened at $36.85 on Friday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $37.59. The stock’s fifty day moving average is $34.20 and its 200 day moving average is $31.28. The stock has a market cap of $10.31 billion, a P/E ratio of 20.82, a P/E/G ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Piper Sandler raised their price objective on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $30.00 to $40.00 in a research note on Monday, January 27th. Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $41.00 to $33.00 in a research note on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Finally, Wells Fargo & Company increased their target price on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.24.

Insider Buying and Selling

In other Exelixis news, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.85% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.